PharmaShots | Incisive News in 3 Shots

Subscribe Now

maat pharma

MaaT Pharma Reports Results from the P-Ib (IASO) Study of MaaT033 for Treating Amyotrophic Lateral Sclerosis (ALS)

MaaT Pharma Reports Results from the P-Ib (IASO) Study of MaaT033 for Treating Amyotrophic Lateral Sclerosis (ALS)

November 26, 2024

MaaT Pharma to Highlight Data from the Early Access Program of MaaT013 to Treat Acute Graft-Versus-Host Disease (aGvHD) at EBMT 2024

MaaT Pharma to Highlight Data from the Early Access Program of MaaT013 to Treat Acute Graft-Versus-Host Disease (aGvHD) at EBMT 20...

April 15, 2024

MaaT Pharma Reports the First Patient Dosing of MaaT033 in P-IIb Trial for Blood Cancer Patients

MaaT Pharma Reports the First Patient Dosing of MaaT033 in P-IIb Trial for Blood Cancer Patients

November 6, 2023

MaaT Pharma Receives Positive Opinion from DSMB for MaaT013 in P-III Trial to Treat Graft Versus Host Disease (GvHD)

MaaT Pharma Receives Positive Opinion from DSMB for MaaT013 in P-III Trial to Treat Graft Versus Host Disease (GvHD)

October 26, 2023

The US FDA Lifts Clinical Hold for MaaT Pharma’s MaaT013 to Treat Acute Graft-versus-Host Disease

The US FDA Lifts Clinical Hold for MaaT Pharma’s MaaT013 to Treat Acute Graft-versus-Host Disease

April 24, 2023

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us